B6 Cont'd

Preferably, the growth factor is VEGF and the cells are endothelial cells, or PDGF and the cells are smooth muscle cells, or FGF and the cells are endothelial cells. Preferably, the effect is monitored colorimetrically, for example using a change in absorbance.

In the Claims:

In accordance with 37 CFR §1.121, please substitute for original claims 8, 14, and 15, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

SUB C1 B7

8. (Amended) A method of identifying one or more indolinone compounds of Formula I that inhibit growth factor-stimulated cell proliferation comprising the following steps:

(a) contacting cells with one or more indolinone compounds;

(b) contacting said cells with one or more growth factors selected from the group consisting of VEGF, PDGF, and FGF;

(c) monitoring an effect upon said cells; and

(d) identifying indolinone compounds of formula I that inhibit growth factor-stimulated cell proliferation.

SUB C2 B8

12. (Amended) A method of identifying one or more indolinone compounds of Formula I that are active in an adjuvant arthritis model in rats comprising the following steps:

(a) administering said one or more indolinone compounds to said rats;

(b) monitoring an effect upon general disease symptoms in said rats; and

(c) identifying indolinone compounds of formula I that are active in an adjuvant arthritis model in rats.

B9 SUB C3

14. (Amended) A method modulating abnormal cell proliferation, modulating the activity of VEGF, FGF, or PDGF on cells *in vivo* or *in vitro* or modulating tyrosine kinase signal transduction, comprising administering to a patient in need of such

treatment a pharmaceutically acceptable composition comprising a therapeutically effective amount of said one more compounds of formula I,

wherein said composition optionally includes one more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:



(I)

wherein,

R_1 is H or alkyl;

R_2 is O or S;

R_3 is H;

R_4, R_5, R_6, and R_7 are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

A is selected from the group consisting of a 4,5,6,7-tetrahydroindole and a five-membered heteroaryl ring, wherein said five-membered ring is selected from the group consisting of thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, I ,3,4-oxadiazole, I ,2,3,4,-oxatriazole, 1,2,3,5-oxatriazole, 1 ,2,3-thiadiazole, 1 ,2,4-thiadiazole, 1 ,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3 ,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said five-membered ring and said tetrahydroindole are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

n is 0-3;

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO_2, and $(CH_2)_nCO_2R$.

15. (Amended) A method of treating or preventing an abnormal condition by administering to a patient in need of such treatment a pharmaceutically acceptable composition comprising a therapeutically effective amount of said one or more compounds of formula I,

wherein said abnormal condition is selected from the group consisting of arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, wherein said composition optionally includes one or more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:



(I)

wherein,

R_1 is H or alkyl;

R_2 is O or S;

R_3 is H;

R_4, R_5, R_6, and R_7 are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R,

SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

A is selected from the group consisting of a 4,5,6,7-tetrahydroindole and a five-membered heteroaryl ring, wherein said five-membered ring is selected from the group consisting of thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, I ,3,4-oxadiazole, I ,2,3,4,-oxatriazole, 1,2,3,5-oxatriazole, 1 ,2,3-thiadiazole, 1 ,2,4-thiadiazole, I ,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3 ,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said five-membered ring and said tetrahydroindole are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

n is 0-3;

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO_2, and $(CH_2)_nCO_2R$.